Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

In a major step towards strengthening cancer care services in the region, Government Medical College (GMC) Jammu has launched a state-of-the-art advanced molecular testing facility for cancer patients ...

Eliana Merle Barclays Bank PLC, Research Division. Hi, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Very excited to have Vertex here with us to discuss ...

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Researchers at Cardiff University have uncovered how a particularly severe form of DNA damage arises—shedding new light on mutation processes that contribute to cancer and inherited genetic conditions ...

Mayo Clinic researchers have identified a rare mutation in the MET gene that can directly cause metabolic dysfunction-associated steatotic liver disease. The mutation disrupts the liver’s ability to ...

Y-complex nucleoporin, Nup107, can regulate ecdysone production by affecting the transcription of Halloween genes and levels of RTK receptor, torso, for the metamorphic transition from larva to pupa.

AstraZeneca’s latest update covers ALAFOSS-01, a first-in-human Phase I/IIa trial of AZD0022 in adults with advanced cancers carrying a KRASG12D mutation. The study aimed to test safety, dosing, and ...